0001209191-18-021318.txt : 20180322 0001209191-18-021318.hdr.sgml : 20180322 20180322175813 ACCESSION NUMBER: 0001209191-18-021318 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180321 FILED AS OF DATE: 20180322 DATE AS OF CHANGE: 20180322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Went Gregory T CENTRAL INDEX KEY: 0001604541 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 18707844 MAIL ADDRESS: STREET 1: C/O ADAMAS PHARMACEUTICALS, INC. STREET 2: 2200 POWELL ST, STE 220 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 750 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 750 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-21 0 0001328143 Adamas Pharmaceuticals Inc ADMS 0001604541 Went Gregory T C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 1 1 0 0 Chief Executive Officer Common Stock 2018-03-21 4 S 0 4541 25.75 D 182610 D Common Stock 195392 I By Trust Common Stock 80000 I Gregory T. Went & Marjorie S. Went ttees 2012 Irr Trust FBO Bridget Elise Went Common Stock 80000 I Gregory T. Went & Marjorie S. Went ttees 2012 Irr Trust FBO Cora Margaret Went Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. The shares were sold at prices ranging from $25.66 to $25.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/Jennifer Rhodes, as Attorney-in-fact 2017-03-22